SpePharm launches MuGard and Xerotin

SpePharm, a firm which specialises in the provision of high medical value therapies in supportive and critical care, has launched two new products in Europe – MuGard and Xerotin.

Xerotin is a ready-to-use mouth moisturising spray which relieves tackles dry mouth symptoms after treatments such as radiotherapy, while MuGard, a muco-adhesive oral rinse, is designed to alleviate lesions and oral mucositis symptoms.

The products will be introduced in countries such as Germany, Italy, the UK and Greece this month and will expand to the rest of the continent within the next 18 months.

Jean-Francois Labbe, chief executive of the group, stated: “We are pleased to announce the introduction of Mugard and Xerotin to meet clear unsatisfied medical needs and provide relief to thousands of patients, already confronted with severe diseases.”

SpePharm was founded in 2006 and last year established offices in Milan, Munich, Oxford and Copenhagen.